• Nuvation Bio has reported that in the first quarter of 2026 it generated US$83.23 million in revenue and US$5.4 million in net income, while the FDA has accepted a supplemental New Drug Application to update IBTROZI’s label with longer-term data in advanced ROS1-positive non-small cell lung cancer.
• These developments, alongside IBTROZI’s addition to NCCN guidelines for CNS cancers and strong intracranial response data, reinforce the company’s emerging role in treating ROS1-positive lung cancer, particularly for patients with brain metastases.
• We’ll now examine how IBTROZI’s long-term efficacy data and label update could influence Nuvation Bio’s investment narrative going forward.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Nuvation Bio Investment Narrative Recap

To own Nuvation Bio, you have to believe IBTROZI can anchor a durable ROS1+ lung cancer franchise while safusidenib slowly progresses toward a second revenue pillar. In the near term, the key catalyst is IBTROZI’s commercial and regulatory execution, with the sNDA review and European expansion in focus. The biggest risk is that IBTROZI faces faster-than-expected competitive pressure or access challenges that leave the business overly reliant on one product.

Among recent developments, the FDA’s acceptance of the IBTROZI sNDA, backed by longer term TRUST-I and TRUST-II data, looks most relevant. It supports the drug’s established clinical profile, aligns with its NCCN guideline status in ROS1+ NSCLC and CNS cancers, and could strengthen the U.S. label ahead of the January 2027 action date. How this interacts with ex U.S. approvals and reimbursement will be important for future revenue contribution.

Yet beneath the strong IBTROZI story, investors should also be aware of the risk that...

Nuvation Bio's narrative projects $427.2 million revenue and $5.2 million earnings by 2028. This requires 151.8% yearly revenue growth and about a $222.7 million earnings increase from -$217.5 million today.

Uncover how Nuvation Bio's forecasts yield a $10.25 fair value, a 113% upside to its current price.

Exploring Other Perspectives

You might see this very differently: before this news, the most optimistic analysts were modeling revenue near US$522.3 million and positive earnings by 2028, while others questioned whether IBTROZI can truly become and remain the standard of care, highlighting how far apart views on Nuvation Bio’s potential can be and why it is worth comparing these contrasting scenarios yourself.

Explore 8 other fair value estimates on Nuvation Bio - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nuvation Bio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Nuvation Bio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nuvation Bio's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.